Tirzepatide versus semaglutide cost is a comparison of specific products and care plans, not just two ingredient names. The price changes with brand, formulation, dose, insurance, manufacturer eligibility, pharmacy, and the services included in treatment.
There is no one medicine that is cheapest for every person. A useful comparison starts with clinically appropriate options and then asks what each actual prescription will cost over time. This guide uses U.S. information checked September 26, 2026 and distinguishes starting offers, ongoing prices, and compounded preparations.
First identify the products being compared
Semaglutide is found in several approved products, including Wegovy and Ozempic, with different indications and formulations. Tirzepatide is the active ingredient in Mounjaro and Zepbound, which also have different approved uses. An ingredient-level search can therefore mix products that are not equivalent choices for the condition being treated.
For weight management, the relevant branded comparison often involves Wegovy and Zepbound. A type 2 diabetes treatment discussion can involve different brands, coverage criteria, and clinical goals. A clinician should identify suitable options before price is used to narrow the choice.
Our GLP-1 guide explains the product families. The Ozempic eligibility article and Mounjaro dosage guide help clarify why those brands should not simply be treated as interchangeable weight-management products.
Current self-pay examples for weight-management products
The table below summarizes selected manufacturer offers from the Wegovy savings page and Zepbound savings page. Eligibility, quantity definitions, and other restrictions apply. These figures are not universal pharmacy prices.
| Product and stage | Current advertised amount | Key condition |
|---|---|---|
| Wegovy injection introductory offer | $199 per eligible monthly fill | Two fills of 0.25 mg or 0.5 mg for qualifying new patients, through December 31, 2026. |
| Wegovy standard injection strengths after introduction | $349 per month | Current listed strengths are 0.25, 0.5, 1, 1.7, and 2.4 mg. |
| Wegovy HD 7.2 mg injection | $399 per month | Separate dose-specific offer and clinical requirements. |
| Wegovy 25 mg daily tablet | $299 per month | Tablet maintenance dose; lower-strength starting prices are different. |
| Zepbound KwikPen 2.5 mg | $299 per month | Starting dose, not an approved maintenance dose. |
| Zepbound KwikPen 5 mg | $399 per month | Confirm applicable program terms. |
| Zepbound KwikPen 7.5–15 mg conditional offer | $449 per month | Higher-strength purchase offer has a refill-purchase timing condition. |
For Zepbound KwikPen, Lilly lists regular prices of $499 for 7.5 mg and $699 for 10, 12.5, and 15 mg if the conditional purchase offer does not apply. The continuing $449 offer requires a refill purchase within 45 days of receipt or delivery of the previous fill under the current terms.
That table gives the comparison a concrete starting point while preserving the important limitations. It does not imply that a reader qualifies for each program or that all listed doses and routes are equally suitable.
Starting prices and maintenance prices answer different questions
A starting dose introduces treatment; it is not necessarily the dose used longer term. A price attached to the lowest strength can therefore understate the ongoing bill.
Wegovy tablets currently start with a $149 offer at 1.5 mg, but the manufacturer’s current 25 mg maintenance-tablet offer is $299. Zepbound’s $299 KwikPen figure applies to 2.5 mg, which is not an approved maintenance dose. The Wegovy dosage chart and Zepbound dosage chart explain the different labeled schedules.
Ask for the amount after introductory eligibility ends and at the dose currently anticipated by the prescriber. If that dose changes, revisit the budget. Do not let a promotion determine whether you remain at an unsuitable dose, skip stages, or advance faster than prescribed.
What is the cheapest GLP-1 without insurance?
The answer depends on which appropriate product and offer you are eligible to use. Among the selected manufacturer weight-management examples above, the current Wegovy tablet maintenance offer is lower than the listed standard injection offers. That does not establish a single cheapest option across all medicines, pharmacies, service fees, and patient circumstances.
For example, a particular route may not fit the treatment plan, an advertised offer may have eligibility restrictions, or a service may add separate clinical charges. Availability, tolerability, and administration also affect whether a lower sticker price represents a practical option.
Use a short list of clinically suitable choices and obtain current quotes for each. Ask the pharmacy to identify the exact program and supply interval. A general search result mixing tablets, injections, diabetes brands, compounded preparations, and introductory offers cannot answer the personal question accurately.
Insurance can change the comparison completely
A person whose plan covers one product may pay less for it than the lower-priced cash option. Someone with a deductible or an excluded weight-management benefit may face a different result. The ingredient name does not determine the benefit.
Ask the insurer about the exact product, indication, formulation, dose, and quantity. Confirm any prior authorization, preferred alternative, pharmacy-network rule, deductible, copay, or coinsurance. A prescription establishes what the clinician ordered; it does not guarantee that a benefit pays for it.
Our BCBS coverage guide provides a practical example of why the individual plan matters. The same principle applies when comparing other insurers: use your current benefit documents and a processed pharmacy quote rather than someone else’s payment.
Compare savings caps, not only advertised minimums
Manufacturer offers that advertise a payment as low as $25 can include limits on how much the program contributes. If the patient’s responsibility is larger than that limit offsets, the actual payment can remain higher.
The current Wegovy commercial offer lists a maximum savings of $100 per month. Lilly’s covered single-dose Zepbound pen offer also has a $100 maximum savings for a one-month prescription, with additional supply and annual rules. Government-program beneficiaries are excluded from these commercial savings-card offers.
The Wegovy cost guide and Zepbound cost guide explain the terms separately. The pharmacy should determine which program can be applied to the actual claim. Do not assume the lowest advertised minimum will apply to every insured patient.
Medicare has a current program distinction
The CMS Medicare GLP-1 Bridge runs from July 1, 2026, through December 31, 2027, under its current terms. Eligible beneficiaries pay a $50 copay for selected products after the applicable clinical and authorization requirements are met.
CMS provider guidance includes Wegovy injections and tablets and Zepbound KwikPen among the eligible products. It does not include Zepbound single-dose pens or vials, and Ozempic is not a Bridge product. Prescription purpose can require the normal Part D route instead.
This can change an eligible person’s comparison, but it should not be described as blanket Medicare coverage for every obesity medicine. The Bridge is outside normal Part D payment flow, and its copay does not count toward the Part D true out-of-pocket calculation. Ask the prescriber and plan which pathway applies.
Make the supply periods comparable
Four weekly doses cover 28 days. Thirty daily tablets cover 30 days when used as prescribed. A clinic’s calendar-month billing can be different again.
Before comparing monthly figures, write down how much medicine is supplied and when the next payment is expected. Twelve four-week supplies cover 48 weeks rather than 52. That difference matters in a longer budget even before promotions, dose changes, or extra charges are considered.
The goal is accurate accounting, not stretching a prescription to match a billing cycle. If timing or supply is unclear, ask the dispensing pharmacy to reconcile the quantity and prescribed schedule.
Add the care surrounding the prescription
A pharmacy price does not necessarily include the clinical program. Telehealth and in-person services can charge differently for evaluations, monitoring, follow-up, membership, supplies, and delivery.
| Item to compare | Details to record for each option |
|---|---|
| Prescription | Exact product, preparation, route, dose, quantity, and pharmacy. |
| Initial payment | Assessment fee and first-fill amount, with introductory conditions. |
| Ongoing payment | Typical refill price, follow-up fee, and any membership. |
| Additional charges | Laboratory work, administration supplies, shipping, or extra appointments. |
| Service access | Who reviews symptoms and how medication questions are answered. |
| Exit terms | Renewal, cancellation, refund, and continuity-of-care arrangements. |
Mark unanswered items as unknown. Treating an unspecified laboratory charge as zero makes the comparison look more complete than it is. Get the important terms in writing before enrolling.
Compounded products need a separate comparison
A compounded preparation containing semaglutide or tirzepatide is not FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound. It is also not an FDA-approved generic equivalent. Shared ingredient names do not establish identical finished products or evidence.
FDA’s compounding overview explains that compounded drugs do not undergo the same FDA premarket review as approved products. The agency’s GLP-1 guidance describes concerns including dosing errors, misleading labeling, and product quality, and recommends compounding when an individual’s medical needs cannot be met by an approved medicine.
If you explore CoreAge Rx’s semaglutide service or tirzepatide service, ask about the exact preparation, pharmacy, clinical rationale, prescribed quantity, total recurring fees, and monitoring. Compare what is actually offered rather than relabeling a service price as a branded-drug discount.
Results and tolerability also affect value
Price alone cannot determine which medicine is medically appropriate. Evidence may involve specific doses, populations, and study durations that differ from the options in a current price table.
Our tirzepatide versus semaglutide results comparison explains relevant research and its limitations. A trial involving particular injectable doses should not be used as proof of an identical comparison for newer tablet or higher-dose formulations.
Side effects and the ability to maintain adequate nutrition also matter. See the semaglutide side-effects guide and tirzepatide questions guide for issues to discuss. A treatment that is unaffordable or poorly tolerated needs a clinical review rather than independent dose or interval changes.
Frequently asked questions
Is tirzepatide always more expensive than semaglutide?
No. Specific current cash offers can differ in that direction, but insurance, formulation, dose, eligibility, and service fees can change the result. Compare actual appropriate prescriptions under the same payment conditions.
Can I compare the two medicines by price per milligram?
That is not a useful measure of equivalent treatment. The medicines and routes have different dosing and clinical evidence. Compare the cost of a prescribed supply and care plan, not an assumed milligram-for-milligram effect.
Is the cheapest first month a good estimate of the year?
No. Starting doses, introductory offers, refill conditions, supply intervals, and additional fees can change the total. Request the expected ongoing amount and what happens when a promotion no longer applies.
Where does Ozempic fit into the comparison?
Ozempic is a separate semaglutide brand with its own approved indications, presentations, and savings terms. The Ozempic cost article covers those details. It should not be substituted into a weight-management comparison solely because the ingredient matches Wegovy.
Choose a sustainable clinical and financial plan
Start with medically appropriate options, get current itemized quotes, and compare the same supply period and included services. That gives the prescriber and patient a practical basis for choosing a plan that can be followed over time.
Check the exact pharmacy offer
- Zepbound at Costco — Compare selected-package quotes and member-pricing terms for single-dose pens and KwikPen.
- Tirzepatide prices on GoodRx — Distinguish a pharmacy cash coupon, manufacturer offer, and clinical-care membership.
Medicare has separate coverage questions
- Medicare Part D and the GLP-1 Bridge — Review indication-based coverage and the separate demonstration rules, eligible products, and copay.
Educational information for adults; individual treatment decisions require a qualified clinician. Sources checked September 26, 2026. Original AI-generated article illustrations depict fictional people and objects, not patient outcomes. Other editorial images are illustrative. Graphics summarize the cited sources.
Further research on this topic
- Tirzepatide vs. Semaglutide: Reading the SURMOUNT-5 Head-to-Head Trial. Read the direct SURMOUNT-5 comparison, including the 72-week weight results and the difference from the earlier SURPASS-2 diabetes trial.
